article thumbnail

Primary Care Provider Perspectives at an Academic Medical Center: Are Telemedicine Visits as Effective as In-person Care? [Survey research or cross-sectional study]

Annals of Family Medicine

Setting: Providers across six Northern California clinic sites surveyed over an 8-week period (March 21-May 16, 2023). Population Studied: 87 primary care providers, including family physicians, internists, nurse practitioners, and physician assistants.

article thumbnail

Migraine headaches: diagnostic and treatment tips

Common Sense Family Doctor

A retrospective analysis of characteristics of 15 consecutive years of code stroke cases at a hospital in Barcelona, Spain, found that patients who were ultimately diagnosed with migraine headache with aura (1.1%) were more likely to be younger, female, and have fewer vascular risk factors than patients with ischemic strokes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

November is Diabetes Awareness Month

Family Physicians of Greeley

of the adult population) in Colorado have diagnosed diabetes, and that every year approximately 34,291 people are newly diagnosed? Type 2 diabetes is by far the most prevalent form of diagnosed diabetes. Prediabetes – is diagnosed when a person’s HgbA1c is between 5.7% Did you know approximately 311,554 (6.9%

article thumbnail

Breast Cancer Awareness

Family Physicians of Greeley

One of the scariest things to ever hear is that you or a loved one has been diagnosed with cancer. Would you be surprised to learn that 1 in 8 women are diagnosed with breast cancer in their lifetime? Breast cancer is the most commonly diagnosed cancer In the United States. What puts you at risk for breast cancer?

PCP 40
article thumbnail

Direct-to-consumer advertising distorts prescription drugs’ benefits and costs

Common Sense Family Doctor

In 1998, a Letter to the Editor in American Family Physician expressed concerns about the relatively new practice of pharmaceutical advertising directly to patients. The annual price of risankizumab is $288,000, so this is still a huge bargain for the company given the potential returns. If it did, why give it for free? All of us.